title: Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.
abstract: Human rhinovirus (RV) infections are the principle cause of common colds and precipitate asthma and COPD exacerbations. There is currently no RV vaccine, largely due to the existence of ∼150 strains. We aimed to define highly conserved areas of the RV proteome and test their usefulness as candidate antigens for a broadly cross-reactive vaccine, using a mouse infection model. Regions of the VP0 (VP4+VP2) capsid protein were identified as having high homology across RVs. Immunization with a recombinant VP0 combined with a Th1 promoting adjuvant induced systemic, antigen specific, cross-serotype, cellular and humoral immune responses. Similar cross-reactive responses were observed in the lungs of immunized mice after infection with heterologous RV strains. Immunization enhanced the generation of heterosubtypic neutralizing antibodies and lung memory T cells, and caused more rapid virus clearance. Conserved domains of the RV capsid therefore induce cross-reactive immune responses and represent candidates for a subunit RV vaccine.
authors.affiliation: Airways Disease Infection Section, National Heart and Lung Institute, Medical Research Council and Asthma United Kingdom Centre in Allergic Mechanisms of Asthma, Centre for Respiratory Infections, Imperial College London, London, United Kingdom.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Glanville
authors.forename: Gary R
authors.initials: GR
authors.lastname: McLean
authors.forename: Bruno
authors.initials: B
authors.lastname: Guy
authors.forename: Valerie
authors.initials: V
authors.lastname: Lecouturier
authors.forename: Catherine
authors.initials: C
authors.lastname: Berry
authors.forename: Yves
authors.initials: Y
authors.lastname: Girerd
authors.forename: Christophe
authors.initials: C
authors.lastname: Gregoire
authors.forename: Ross P
authors.initials: RP
authors.lastname: Walton
authors.forename: Rebecca M
authors.initials: RM
authors.lastname: Pearson
authors.forename: Tatiana
authors.initials: T
authors.lastname: Kebadze
authors.forename: Nicolas
authors.initials: N
authors.lastname: Burdin
authors.forename: Nathan W
authors.initials: NW
authors.lastname: Bartlett
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Almond
authors.forename: Sebastian L
authors.initials: SL
authors.lastname: Johnston
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D001249:Asthma / Q000276:immunology / Q000821:virology; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D003139:Common Cold / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D003429:Cross Reactions; D005260:Female; D006801:Humans; D007114:Immunization; D008168:Lung / Q000276:immunology* / Q000821:virology; D051379:Mice; D029424:Pulmonary Disease, Chronic Obstructive / Q000276:immunology / Q000821:virology; D012229:Rhinovirus / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D014765:Viral Vaccines